Innovent Biologics Inc
HKEX:1801

Watchlist Manager
Innovent Biologics Inc Logo
Innovent Biologics Inc
HKEX:1801
Watchlist
Price: 34.95 HKD -0.71% Market Closed
Market Cap: 57.2B HKD
Have any thoughts about
Innovent Biologics Inc?
Write Note

Innovent Biologics Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Innovent Biologics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Innovent Biologics Inc
HKEX:1801
EPS (Diluted)
ÂĄ0
CAGR 3-Years
6%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
EPS (Diluted)
-ÂĄ4
CAGR 3-Years
17%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
EPS (Diluted)
ÂĄ2
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-5%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
EPS (Diluted)
ÂĄ1
CAGR 3-Years
-36%
CAGR 5-Years
3%
CAGR 10-Years
34%
Imeik Technology Development Co Ltd
SZSE:300896
EPS (Diluted)
ÂĄ6
CAGR 3-Years
35%
CAGR 5-Years
52%
CAGR 10-Years
N/A
No Stocks Found

Innovent Biologics Inc
Glance View

Market Cap
56.9B HKD
Industry
Biotechnology

In the bustling landscape of the biotechnology industry, Innovent Biologics Inc. stands out as a dynamic player committed to advancing precision medicine. Founded in 2011, this Chinese-based company has carved out a significant niche in the development of monoclonal antibodies for oncology, metabolic disorders, and autoimmune diseases. Innovent sought to bridge the gap between innovation and affordability, an ambitious vision fueled by strategic collaborations with global pharma giants and local research centers. The company’s flagship product, Tyvyt (sintilimab), is a testament to their pioneering spirit—a PD-1 inhibitor developed in partnership with Eli Lilly, which gained approval for the treatment of various cancers in China. Innovent leverages its robust in-house R&D capabilities and partnerships to craft an extensive pipeline of potential therapies, positioning itself as a linchpin in the race to address unmet medical needs across its target markets. Innovent Biologics generates revenue through strategic licensing agreements, collaborative development programs, and direct sales of its commercialized therapies. It adopts a multinational partnership model that allows it to both share development costs and tap into broader distribution channels, thus accelerating growth while minimizing financial risk. By focusing on biopharmaceuticals that address prevalent health concerns, Innovent capitalizes on the rising demand for innovative healthcare solutions in China and beyond. Furthermore, the company's vertically integrated infrastructure—from research to commercialization—ensures optimized costs and sustained profitability in a competitive industry landscape. Innovent’s financial trajectory is buoyed by its ability to balance cutting-edge scientific innovation with strategic market positioning, underscoring its reputation as a formidable force in global biotech.

Intrinsic Value
47.62 HKD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Innovent Biologics Inc's EPS (Diluted)?
EPS (Diluted)
-0.8 CNY

Based on the financial report for Jun 30, 2024, Innovent Biologics Inc's EPS (Diluted) amounts to -0.8 CNY.

What is Innovent Biologics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
32%

Over the last year, the EPS (Diluted) growth was 11%. The average annual EPS (Diluted) growth rates for Innovent Biologics Inc have been 6% over the past three years , 32% over the past five years .

Back to Top